Search results
Nov 14, 2022 · SINGAPORE – BioNTech on Monday confirmed that its first mRNA manufacturing plant in Singapore will be operational in late 2023, with the facility also serving as the German company’s regional...
Nov 13, 2022 · First mRNA manufacturing facility in Singapore will create regional manufacturing capacities in support of BioNTech’s growing pipeline of mRNA-based vaccines and therapeutics across Asia Pacific region for both clinical and commercial scale.
May 10, 2021 · BioNTech to establish first regional hub in Asia Pacific region in Singapore. Planned state-of-the-art manufacturing site will support global supply of mRNA-based vaccines and therapeutics and provide a rapid response capability for south east Asia against potential future pandemic threats.
May 10, 2021 · SINGAPORE - BioNTech, the vaccine maker that has partnered with Pfizer on its Covid-19 shot, will be designating Singapore as its regional headquarters for South-east Asia, and will set up an...
May 10, 2021 · BIONTECH will pump in "hundreds of millions of dollars" to set up its South-east Asia headquarters and open a vaccine manufacturing facility in Singapore, as part of plans to establish a footprint in Asia.
In November 2022, we announced that our Singapore affiliate BioNTech Pharmaceuticals Asia Pacific Pte. Ltd. had entered into an agreement with Novartis Singapore Pharmaceutical Manufacturing Pte. Ltd. to acquire one of its GMP-certified manufacturing facilities.
Nov 14, 2022 · BioNTech has acquired a manufacturing facility from Novartis in Singapore which it will retrofit for mRNA vaccine production.
May 10, 2021 · SINGAPORE — BioNTech announced Monday it will set up its Southeast Asia headquarters in Singapore, and will build a manufacturing facility in the city-state to produce its messenger RNA...
Nov 14, 2022 · Nov 14 (Reuters) - BioNTech SE (22UAy.DE), the German biotech that developed a widely used COVID-19 vaccine with Pfizer Inc (PFE.N), acquired a manufacturing facility in Singapore, its first...
Mar 1, 2022 · Its new facility in Singapore is a welcome addition to the country's healthcare system, and is in line with efforts to strengthen capabilities across the biopharmaceutical manufacturing value chain, said Ms Goh Wan Yee, senior vice-president of healthcare at EDB.
